hot topics clinical medicine acha annual meeting boston, ma may 31, 2013

Hot TopicsClinical Medicine

ACHA Annual Meeting

Boston, MA

May 31, 2013

Boston University Slideshow Title Goes Here

Important publication-LAST

Consensus Guidelines (2012) The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations From the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology

Journal of Lower Genital Tract Disease, July 2012

Hot Topics, Clinical Medicine

2

04/19/23


Basic intervals, normal pap history

Don’t start paps until 21 21-29 every 3 years, no co-testing 30-64 every 3 years or every 5 years with co-testing Over 65 no testing


3

04/19/23



4

04/19/23

Unsatisfactory cytology on pap

With liquid-based technology, most reasons for unsatisfactory cytology are eliminated EXCEPT inadequate cells

Don’t use negative HPV co-testing as a reason not to repeat

Repeat test in 2-4 months



5

04/19/23


Absent EC/TZ

Prior recommendation was early repeat

Under 30, manage as normal

Over 30, co-test or manage as normal If negative co-test,

routine repeat If positive co-test,

repeat cyto+co-test 1 year or

Genotype for 16, 18


6

04/19/23



7

04/19/23


New concept


8

04/19/23

16, 18?


Test Name Result Flag(s) Reference Range Reported Date Footnote CLINICAL INFORMATION: SEE NOTE ALL NL PAPS LMP: 4/6/2013 PREV. PAP: N/A PREV. BX: N/A SOURCE: Cervix STATEMENT OF ADEQUACY: SEE NOTE Satisfactory for evaluation. Endocervical/transformation zone component present. INTERPRETATION/RESULT: SEE NOTE Negative for intraepithelial lesion or malignancy. INFECTION: SEE NOTE Shift in vaginal flora suggestive of bacterial vaginosis. COMMENT: SEE NOTE This Pap test has been evaluated with computer assisted technology. CYTOTECHNOLOGIST: SEE NOTE CXP, CT(ASCP) HPV DNA (HIGH RISK) DETECTED A (NOT DETECTED) High-risk HPV types 16,18,31,33,35,39,45,51,52,56,58,59, or 68 may cause cervical cancer or itsprecursors.The analytical

performance characteristics of thisassay, when used to test SurePath or vaginal specimens,have been determined by Quest Diagnostics.Methodology: Hybrid Capture with Signal Amplification.


9

04/19/23



10

04/19/23


New concept


11

04/19/23



12

04/19/23



13

04/19/23



14

04/19/23

hot topics clinical medicine acha annual meeting boston, ma may 31, 2013

Documents